Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

Giulia Petroni; Guido Kroemer; Lorenzo Galluzzi

doi:10.1016/j.trecan.2021.01.005

Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

Giulia Petroni, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journal › Short survey › peer-review

Abstract

Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.

Original language	English
Pages (from-to)	179-181
Number of pages	3
Journal	Trends in Cancer
Volume	7
Issue number	3
DOIs	https://doi.org/10.1016/j.trecan.2021.01.005
State	Published - Mar 2021
Externally published	Yes

Keywords

cyclophosphamide
KP mice
lung adenocarcinoma
radiation therapy
ROR1
tumor-associated macrophages

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2021.01.005

Cite this

@article{33d1f4dd08bc4b1a8c3696a5d2761fc7,

title = "Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy",

abstract = "Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.",

keywords = "cyclophosphamide, KP mice, lung adenocarcinoma, radiation therapy, ROR1, tumor-associated macrophages",

author = "Giulia Petroni and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = mar,

doi = "10.1016/j.trecan.2021.01.005",

language = "English",

volume = "7",

pages = "179--181",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

AU - Petroni, Giulia

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2021/3

Y1 - 2021/3

N2 - Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.

AB - Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.

KW - cyclophosphamide

KW - KP mice

KW - lung adenocarcinoma

KW - radiation therapy

KW - ROR1

KW - tumor-associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85100297218&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2021.01.005

DO - 10.1016/j.trecan.2021.01.005

M3 - Short survey

C2 - 33518493

AN - SCOPUS:85100297218

SN - 2405-8033

VL - 7

SP - 179

EP - 181

JO - Trends in Cancer

JF - Trends in Cancer

IS - 3

ER -

Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this